I agree that this site is using cookies. You can find further informations here.
X
Yanagitani, Noriko
143  results:
Search for persons X
?
1

Efficacy of osimertinib in patients with EGFR‐mutation posi..:

Kiritani, Ayu ; Amino, Yoshiaki ; Uchibori, Ken...
Thoracic Cancer.  , 2024
Link: https://doi.org/10.1111/..
 
?
2

Distinction of ALK fusion gene‐ and EGFR mutation‐positive ..:

Akita, Takahiro ; Ariyasu, Ryo ; Kakuto, Sho...
Thoracic Cancer.  15 (2024)  10 - p. 788-796 , 2024
Link: https://doi.org/10.1111/..
 
?
3

KEYNOTE-434 part B: A phase 1 study evaluating the combinat..:

Yamamoto, Noboru ; Satouchi, Miyako ; Doi, Toshihiko...
Investigational New Drugs.  42 (2024)  3 - p. 261-271 , 2024
Link: https://doi.org/10.1007/..
 
?
4

Prophylactic pegfilgrastim reduces febrile neutropenia in r..:

Miura, Keita ; Yamaguchi, Ou ; Mori, Keita...
Scientific Reports.  14 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
5

Real-World Outcome Analysis of Patients With Stage IV NSCLC..:

Ariyasu, Ryo ; Kakuto, Sho ; Miyadera, Keiki...
JTO Clinical and Research Reports.  4 (2023)  6 - p. 100524 , 2023
Link: https://doi.org/10.1016/..
 
?
6

A Retrospective, Multicenter, Observational Study to Evalua..:

Goto, Yasushi ; Kenmotsu, Hirotsugu ; Tamiya, Motohiro...
JTO Clinical and Research Reports.  4 (2023)  5 - p. 100508 , 2023
Link: https://doi.org/10.1016/..
 
?
7

Soluble interleukin-2 receptor as a predictive biomarker fo..:

Tozuka, Takehiro ; Yanagitani, Noriko ; Yoshida, Hiroshi...
Investigational New Drugs.  41 (2023)  3 - p. 411-420 , 2023
Link: https://doi.org/10.1007/..
 
?
8

Multicentre real-world data of ramucirumab plus docetaxel a..:

Nakamura, Atsushi ; Yamaguchi, Ou ; Mori, Keita...
European Journal of Cancer.  184 (2023)  - p. 62-72 , 2023
Link: https://doi.org/10.1016/..
 
?
9

NOTCH1 and CREBBP co‐mutations negatively affect the benefi..:

Ikeda, Satoshi ; Tsuboi, Masahiro ; Sakai, Kazuko...
Molecular Oncology.  18 (2023)  2 - p. 305-316 , 2023
Link: https://doi.org/10.1002/..
 
?
10

Effectiveness and Safety of Atezolizumab Monotherapy in Pre..:

Miura, Satoru ; Nishio, Makoto ; Akamatsu, Hiroaki...
JTO Clinical and Research Reports.  4 (2023)  3 - p. 100484 , 2023
Link: https://doi.org/10.1016/..
 
?
11

Subsequent treatment for locally advanced non-small-cell lu..:

Hasegawa, Tsukasa ; Ariyasu, Ryo ; Tanaka, Hisashi...
Cancer Chemotherapy and Pharmacology.  92 (2023)  1 - p. 29-37 , 2023
Link: https://doi.org/10.1007/..
 
?
12

Clinical characteristics of patients with KRAS mutation det..:

Amino, Yoshiaki ; Low, Siew‐Kee ; Ninomiya, Hironori...
Thoracic Cancer.  14 (2023)  33 - p. 3317-3322 , 2023
Link: https://doi.org/10.1111/..
 
?
13

Soluble PD-L1 works as a decoy in lung cancer immunotherapy..:

Sagawa, Ray ; Sakata, Seiji ; Gong, Bo...
JCI Insight.  7 (2022)  1 - p. , 2022
Link: https://doi.org/10.1172/..
 
?
14

Real-World Data Analysis of Pembrolizumab Monotherapy for N..:

Terai, Hideki ; Soejima, Kenzo ; Shimokawa, Asanao...
JTO Clinical and Research Reports.  3 (2022)  11 - p. 100404 , 2022
Link: https://doi.org/10.1016/..
 
?
15

Fibroblast growth factor receptor 3 overexpression mediates..:

Sakashita, Takuya ; Yanagitani, Noriko ; Koike, Sumie...
Cancer Science.  113 (2022)  11 - p. 3888-3900 , 2022
Link: https://doi.org/10.1111/..
 
1-15